The natural molecular vaccine adjuvant QS-21 is in increasing demand for several approved vaccines, including shingles, malaria, and—outside the United States—COVID-19. More than a dozen vaccines are being developed against those conditions as well as influenza, hepatitis B virus, human papillomavirus, HIV/AIDS, tuberculosis, non-small-cell lung carcinoma (NSCLC), and melanoma. Purification, however, has been challenging.
Now, scientists at the Access to Advanced Health Institute (AAHI) say they have developed a simple and efficient method that produces high yields of QS-21 at more than 97% purity under GMP manufacturing conditions. The challenge to date has been the nature of QS-21 itself.
